Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials von Newlands, E.S., Stevens, M.F.G., Wedge, S.R., Wheelhouse, R.T., Brock, C.

Volltext

110 EMT Followed in Three Dimensions in Vitro von Cygan, P.A, Grabowska, A.M, Stolnik-Trenkic, S, Elvin, P, Wedge, S.R, Watson, S

Volltext

Clinical Trials Review: Molecular Targeted Agents in Combination with Radiotherapy in Solid Tumors: A Pharmaceutical Industry Perspective von Ataman, O, Wedge, S.R, Sambrook, S.J, Wilks, C, Taylor, A

Volltext

A minimum core outcome dataset for the reporting of preclinical chemotherapeutic drug studies: Lessons learned from multiple discordant methodologies in the setting of colorectal c... von West, M.A, Roman, A, Sayan, E, Primrose, JN, Wedge, SR, Underwood, TJ, Mirnezami, AH

Volltext

135 INVITED Combining molecular targeted agents with radiotherapy von Wedge, S.R, Williams, K.J, Stratford, I.J

Volltext

Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macrom... von Pradel, C, Siauve, N, Bruneteau, G, Clement, O, de Bazelaire, C, Frouin, F, Wedge, S.R, Tessier, J.L, Robert, P.H, Frija, G, Cuenod, C.A

Volltext

ZM323881, a Novel Inhibitor of Vascular Endothelial Growth Factor-Receptor-2 Tyrosine Kinase Activity von WHITTLES, C.E., POCOCK, T.M., WEDGE, S.R., KENDREW, J., HENNEQUIN, L.F., HARPER, S.J., BATES, D.O.

Volltext

The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma von DREVS, J, KONERDING, M. A, WOLLOSCHECK, T, WEDGE, S. R, RYAN, A. J, OGILVIE, D. J, ESSER, N

Volltext

Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer von Goodlad, R.A., Ryan, A.J., Wedge, S.R., Pyrah, I.T., Alferez, D., Poulsom, R., Smith, N.R., Mandir, N., Watkins, A.J., Wilkinson, R.W.

Volltext

ZM323881, a Novel Inhibitor of Vascular Endothelial Growth Factor-Receptor-2 Tyrosine Kinase Activity von WHITTLES, C.E., POCOCK, T.M., WEDGE, S.R., KENDREW, J., HENNEQUIN, L.F., HARPER, S.J., BATES, D.O.

Volltext

160 Antitumor therapy with VEGF receptor tyrosine kinase inhibitor ZD6474 in a mouse model of intestinal cancer von Goodlad, R.A., Ryan, A., Watson, J., Wedge, S.R., Pyrah, I.T., Mandir, N., Wilkinson, R.W.

Volltext

Measurement of 5,10-dideaza-5,6,7,8-tetrahydrofolate (lometrexol) in human plasma and urine by high-performance liquid chromatography von Wedge, S.R., Laohavinij, S., Taylor, G.A., Newell, D.R.

Volltext

Characterization of the fatigue behavior of additive friction stir-deposition AA2219 von Anderson-Wedge, K., Avery, D.Z., Daniewicz, S.R., Sowards, J.W., Allison, P.G., Jordon, J.B., Amaro, R.L.

Volltext

Fatigue crack growth behavior of additively manufactured 17-4 PH stainless steel: Effects of build orientation and microstructure von Nezhadfar, P.D., Burford, Emma, Anderson-Wedge, Kathryn, Zhang, Bin, Shao, Shuai, Daniewicz, S.R., Shamsaei, Nima

Volltext

Improved high cycle fatigue performance of additively manufactured 17-4 PH stainless steel via in-process refining micro-/defect-structure von Nezhadfar, P.D., Anderson-Wedge, Kathryn, Daniewicz, S.R., Phan, Nam, Shao, Shuai, Shamsaei, Nima

Volltext

Characterization of the evolution of 2219-T87 aluminum as a function of the friction stir welding process von Anderson-Wedge, K., Stubblefield, G., Zhu, N., Long, B., Daniewicz, S.R., Allison, P., Sowards, J., Rodriguez, O., Amaro, R.

Volltext

165 AZD2171, a potent VEGF receptor tyrosine kinase inhibitor, combined with mechanistically distinct antitumor therapies in vivo von Wedge, S., Kendrew, J., Valentine, P.J., Brave, S.R., Barnett, S., Jurgensmeier, J.M., Hennequin, L.F., Ogilvie, D.J.

Volltext